Three-drug combo for FLT3-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of leukemia called AML (or MDS turning into AML) with a specific change in the FLT3 gene.
- You are at least 15 years old.
- You are in fairly good physical shape (able to do most daily activities).
- Your liver, kidneys, and heart function must be within acceptable limits on recent blood tests and an echocardiogram.
- You cannot have already received strong chemotherapy for this leukemia, or have another active cancer, serious heart disease, or an active serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial compares a new combination treatment to standard chemotherapy plus a targeted drug (called an FLT3 inhibitor) in people with AML that has a FLT3 mutation. The goal is to see if the new approach works better and helps improve outcomes.
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
Hear when a new FLT3 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.